Dallas, TX - The fibrate hypolipemic fenofibrate failed to significantly reduce the primary end point (CHD death or nonfatal MI) vs placebo in diabetic patients in the Fenofibrate Intervention and ...

Fenofibrate as an adjunct to statins was associated with lower risks for all-cause mortality and cardiovascular disease among individuals with type 2 diabetes. Fenofibrate as an adjunct to statin ...

WHAT: A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of "good" ...

Active ingredient: Fenofibric acid (as choline fenofibrate) 45 mg, 135 mg; delayed-release caps. Indications: Adjunct to diet: In combination with a statin, to reduce triglycerides (TG) and increase ...

Clin Lipidology. 2009;4(3):331-341. Furthermore, at 6 months significant in-group changes were observed for body weight, BMI and waist circumference in all treatment groups, but these reductions were ...

Recent research suggests that the majority of side effects commonly linked to statins are not, in fact, caused by the medication itself. A comprehensive study, published in The Lancet, examined data ...